Alzinova Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Alzinova's earnings have been declining at an average annual rate of -26.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 14% per year.
Información clave
-26.9%
Tasa de crecimiento de los beneficios
12.0%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 0.7% |
Tasa de crecimiento de los ingresos | 14.0% |
Rentabilidad financiera | -17.4% |
Margen neto | -121.4% |
Próxima actualización de resultados | 14 Nov 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Alzinova. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 24 | 15 | -18 | 33 | 0 |
31 Mar 24 | 18 | -17 | 35 | 0 |
31 Dec 23 | 20 | -16 | 36 | 0 |
30 Sep 23 | 17 | -16 | 34 | 0 |
30 Jun 23 | 17 | -16 | 33 | 0 |
31 Mar 23 | 14 | -15 | 29 | 0 |
31 Dec 22 | 17 | -13 | 30 | 0 |
30 Sep 22 | 16 | -11 | 27 | 0 |
30 Jun 22 | 15 | -9 | 25 | 0 |
31 Mar 22 | 17 | -8 | 26 | 0 |
31 Dec 21 | 17 | -8 | 25 | 0 |
30 Sep 21 | 18 | -7 | 26 | 0 |
30 Jun 21 | 19 | -7 | 26 | 0 |
31 Mar 21 | 16 | -6 | 22 | 0 |
31 Dec 20 | 15 | -6 | 21 | 0 |
30 Sep 20 | 13 | -7 | 20 | 0 |
30 Jun 20 | 12 | -6 | 18 | 0 |
31 Mar 20 | 11 | -7 | 18 | 0 |
31 Dec 19 | 7 | -6 | 13 | 0 |
30 Sep 19 | 5 | -5 | 10 | 0 |
30 Jun 19 | 6 | -5 | 12 | 0 |
31 Mar 19 | 8 | -5 | 13 | 0 |
31 Dec 18 | 9 | -4 | 14 | 0 |
30 Sep 18 | 11 | -3 | 14 | 0 |
30 Jun 18 | 10 | -3 | 13 | 0 |
31 Mar 18 | 8 | -2 | 11 | 0 |
31 Dec 17 | 6 | -3 | 8 | 0 |
30 Sep 17 | 5 | -3 | 8 | 0 |
30 Jun 17 | 4 | -3 | 8 | 0 |
31 Mar 17 | 5 | -4 | 8 | 0 |
31 Dec 16 | 5 | -3 | 8 | 0 |
30 Sep 16 | 5 | -4 | 8 | 0 |
30 Jun 16 | 4 | -4 | 7 | 0 |
31 Mar 16 | 2 | -3 | 6 | 0 |
31 Dec 15 | 1 | -3 | 4 | 0 |
31 Dec 14 | 1 | 0 | 1 | 0 |
31 Dec 13 | 1 | 0 | 1 | 0 |
Ingresos de calidad: ALZ is currently unprofitable.
Margen de beneficios creciente: ALZ is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ALZ is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year.
Acelerando crecimiento: Unable to compare ALZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ALZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rentabilidad financiera
Alta ROE: ALZ has a negative Return on Equity (-17.42%), as it is currently unprofitable.